Literature DB >> 27504298

Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy.

Sumit Grover1, Pavneet Kaur Selhi2, Neena Sood3, Jasvinder Singh Sandhu4, Harpreet Kaur2.   

Abstract

Multiple myeloma is a disorder of plasma cells which can involve kidneys in the form of cast nephropathy. Neoplastic plasma cells produce either complete immunoglobulins or fragments of immunoglobulins leading to a monoclonal spike in the serum and/or Bence Jones proteinuria. Very few patients present as non-secretory myeloma when no immunoglobulins (M spike) are produced or only light chains are secreted which can only be detected in urine. Acute renal failure due to cast nephropathy can rarely be the first presentation of multiple myeloma. We here in report a case in which primary diagnosis of multiple myeloma was made on renal biopsy due to its characteristic histomorphology. The diagnosis was later on supported by presence of neoplastic plasma cells in the aspirate and biopsy of bone marrow.

Entities:  

Keywords:  Fractured casts; Kidney biopsy; Plasma cell dyscrasia; Protein electrophoresis; Renal failure

Year:  2016        PMID: 27504298      PMCID: PMC4963658          DOI: 10.7860/JCDR/2016/19060.7925

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  20 in total

1.  Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney.

Authors:  Kolitha Basnayake; Chee Kay Cheung; Michael Sheaff; William Fuggle; Dia Kamel; Sandra Nakoinz; Colin A Hutchison; Mark Cook; John Stoves; Arthur R Bradwell; Paul Cockwell
Journal:  J Clin Pathol       Date:  2010-10       Impact factor: 3.411

2.  Myeloma cast nephropathy: immunohistochemical and lectin studies.

Authors:  D A Start; F G Silva; L D Davis; V D'Agati; C L Pirani
Journal:  Mod Pathol       Date:  1988-09       Impact factor: 7.842

3.  Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

Authors:  Jonathan L Kaufman; Ajay Nooka; Mark Vrana; Charise Gleason; L Thompson Heffner; Sagar Lonial
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

4.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

5.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.

Authors:  Bruno Paiva; Joaquin Martinez-Lopez; Maria-Belen Vidriales; Maria-Victoria Mateos; Maria-Angeles Montalban; Elena Fernandez-Redondo; Lourdes Alonso; Albert Oriol; Ana-Isabel Teruel; Raquel de Paz; José-Garcia Laraña; Enrique Bengoechea; Alejandro Martin; Joaquin Diaz Mediavilla; Luis Palomera; Felipe de Arriba; Joan Bladé; Alberto Orfao; Juan-Jose Lahuerta; Jesus F San Miguel
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

6.  Multiple myeloma: review of 869 cases.

Authors:  R A Kyle
Journal:  Mayo Clin Proc       Date:  1975-01       Impact factor: 7.616

Review 7.  Biology and treatment of multiple myeloma.

Authors:  R Niesvizky; D Siegel; J Michaeli
Journal:  Blood Rev       Date:  1993-03       Impact factor: 8.250

8.  Tamm Horsfall protein binds to a single class of carbohydrate specific receptors on human neutrophils.

Authors:  D B Thomas; M Davies; J R Peters; J D Williams
Journal:  Kidney Int       Date:  1993-08       Impact factor: 10.612

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  Nonsecretory multiple myeloma.

Authors:  Seshikanth Middela; Prakash Kanse
Journal:  Indian J Orthop       Date:  2009-10       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.